journal
Journals Australasian Journal of Dermat...

Australasian Journal of Dermatology

https://read.qxmd.com/read/38646889/a-photo-distributed-rash-and-eczematous-eruptions-in-two-siblings-a-diagnostic-conundrum
#1
Kittu Malhi, Akash Mustari, Sukhdeep Singh, Anoop Kumar, Pandiarajan Vignesh, Dipankar De, Sanjeev Handa, Rahul Mahajan
No abstract text is available yet for this article.
April 22, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38641920/evaluating-the-role-of-bone-scan-in-diagnosing-calciphylaxis-in-practice-a-retrospective-case-series-of-patients-who-were-clinically-managed-for-calciphylaxis-despite-resulting-negative-on-initial-biopsy
#2
JOURNAL ARTICLE
Emilee Herringshaw, Maximilian Kinne, Renee Joyce, Fnu Nutan
No abstract text is available yet for this article.
April 20, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38629787/dupilumab-for-chronic-actinic-dermatitis-a-case-series-and-review-of-the-literature
#3
JOURNAL ARTICLE
Zachary Holmes, Peter Foley, Chris Baker, Benjamin S Daniel
No abstract text is available yet for this article.
April 17, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38623950/use-of-biologics-for-psoriasis-in-solid-organ-transplant-recipients
#4
JOURNAL ARTICLE
Marta Costa Blasco, Claire Doyle, Sophie Diong, Siona Ni Raghallaigh
Biologics have significantly advanced the treatment of inflammatory disorders, including psoriasis. However, their use in immunosuppressed patients, such as those with solid-organ transplants, is less understood. These patients often face dermatological issues, but inflammatory skin diseases are rare due to their immunosuppressive treatments. Our study aims to assess biologics' effectiveness in such immunocompromised patients. We report a case from our institution of a 29-year-old man with a history of psoriasis, who underwent a kidney transplant and later developed erythroderma...
April 16, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38616534/successful-use-of-adalimumab-in-treating-granuloma-faciale-resistant-to-traditional-therapies
#5
JOURNAL ARTICLE
Martina Mussi, Corrado Zengarini, Filippo Viviani, Lidia Sacchelli, Alessandro Pileri, Federico Bardazzi
No abstract text is available yet for this article.
April 14, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38616498/dermatitis-and-prolonged-dysesthesia-from-the-poisonous-wood-nettle-dendrocnide-meyeniana-urticaceae
#6
Johannes F Dayrit, Bryan Edgar K Guevara, Lunardi Bintanjoyo, Scott A Norton
No abstract text is available yet for this article.
April 14, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38616484/successful-treatment-of-dyshidrotic-palmoplantar-eczema-with-tralokinumab
#7
Nisha V Parmar, Anwar Al Hammadi
Dyshidrotic palmoplantar eczema or pompholyx is considered to be a part of the spectrum of atopic dermatitis with a significant impact on the quality of life and limited treatment options. Tralokinumab is a new fully human monoclonal antibody which neutralizes interleukin 13, a chief cytokine in itch pathogenesis and skin barrier defects. Tralokinumab is FDA-approved for the treatment of atopic dermatitis in adults and EMA-approved for the treatment of atopic dermatitis in adults and adolescents. We, hereby, report a 40-year-old female with severe dyshidrotic palmoplantar eczema who was successfully treated with tralokinumab...
April 14, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38597123/switch-from-adalimumab-to-brodalumab-as-a-possible-trigger-factor-for-the-onset-of-pyoderma-gangrenosum
#8
Giorgia Salvia, Matteo Bevilacqua, Flavia Manzo Margiotta, Alessandra Michelucci, Giammarco Granieri, Cristian Fidanzi, Valentina Dini, Marco Romanelli, Carlo Mazzatenta
No abstract text is available yet for this article.
April 10, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38597096/brodalumab-for-moderate-severe-hidradenitis-suppurativa-an-open-label-multicentric-cohort-study-in-real-clinical-practice
#9
JOURNAL ARTICLE
Guiovana Fernanda Osorio-Gómez, Juan Ortiz-Álvarez, Delia Diaz-Ceca, Cesar Guijarro-Sánchez, Julián Conejo-Mir Sánchez, Pablo Fernández Crehuet
INTRODUCTION: The use of biological therapy is becoming increasingly common in patients with hidradenitis suppurativa (HS). Levels of serum TNF-alfa and IL17 support the role of an immune system dysregulation in the pathogenesis of HS. Brodalumab targets the receptor A of IL-17, thus having a promising role in the treatment of HS. MATERIAL AND METHODS: A multicenter retrospective observational open-label study was conducted in two tertiary hospitals. Adults with moderate to severe HS under treatment with brodalumab 210 mg at week 0, 1, 2 and then every 2 weeks were included and assessed at weeks 0 and 16 which was the median follow-up time...
April 10, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38587232/efficacy-and-safety-of-tralokinumab-in-the-treatment-of-head-and-neck-pattern-atopic-dermatitis-a-multicentre-study-of-12-patients
#10
JOURNAL ARTICLE
Francisco José Navarro-Triviño, María Salazar-Nievas, Juan Luis Sanz-Cabanillas, Cintia Arjona-Aguilera
BACKGROUND/OBJECTIVES: The evaluation of the efficacy and safety of new molecules for atopic dermatitis (AD) in real clinical practice is very important to obtain information that clinical trials (EECC) lack. The pattern of AD in the head and neck (H&N) continues to be a challenge in treatment today, despite the new molecules, and real-life data on the use of tralokinumab is still missing. This is the first daily practice study of tralokinumab treatment in patients with H&N AD pattern...
April 8, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38572867/can-we-manage-the-melanocytic-lesions-with-peripheral-globules-according-to-the-grade-of-dysplasia
#11
JOURNAL ARTICLE
Ceylan Avcı, Gülfem Akın, Banu Lebe, Mustafa Turhan Şahin, Emel Fetil
BACKGROUND/OBJECTIVES: Although excision of melanocytic nevi with high-grade dysplasia is recommended by the World Health Organization (WHO), clinical studies investigating the approach based on the grading dysplasia of melanocytic lesions with peripheral globules (PGs) are lacking. We investigated the grades of dysplasia and their distinguishable dermoscopic and clinical features to provide accurate data for managing these lesions. METHODS: We retrospectively classified histologically confirmed melanocytic lesions with PGs according to the 2018 WHO Classification of Skin Tumours criteria in a university hospital in Turkey...
April 4, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38572842/severe-cutaneous-adverse-reactions-associated-with-the-immune-checkpoint-inhibitors-a-case-non-case-analysis-using-the-food-and-drug-administration-adverse-event-reporting-system
#12
JOURNAL ARTICLE
Hannah Godfrey, Patrick Jedlowski, Rebecca Thiede
BACKGROUND/OBJECTIVES: The immune checkpoint inhibitors (ICIs) have been increasingly associated with severe cutaneous adverse reactions (SCARs). These reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalized exanthematous pustulosis (AGEP) are uncommon but potentially lethal. Despite the severity of these reactions and growing association with the ICIs, their specific risk and mortality rates have been largely unexplored...
April 4, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38544290/extensive-and-deep-granulomatous-ulcers-as-an-atypical-manifestation-of-cartilage-hair-hypoplasia-syndrome-a-diagnostic-and-therapeutic-challenge
#13
JOURNAL ARTICLE
Eduardo Rozas-Muñoz, Rodrigo Blamey-Diaz, Ana Maria Gallardo-Olivos, Javiera Jerez, Juan-Andres Madariaga
Cartilage hypoplasia syndrome is a primary immunodeficiency disease characterized by short stature, hypoplastic hair and a variable degree of immunodeficiency. Noninfectious cutaneous granulomas represent an uncommon yet well-recognized manifestation within the spectrum of primary immunodeficiency diseases. However, cutaneous granulomas as a manifestation of cartilage-hair hypoplasia syndrome, are extremely rare. We present a case of a middle-aged man with cartilage hypoplasia syndrome featuring cutaneous granulomas, manifesting as chronic, extensive and deep cutaneous ulcers...
March 27, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38530151/the-representation-of-skin-of-colour-in-the-australasian-journal-of-dermatology
#14
JOURNAL ARTICLE
Harriet Kennedy, Loimata Fa'alogo-Lilo
No abstract text is available yet for this article.
March 26, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38530143/naevoid-miliaria-profunda-successfully-treated-with-botulinum-toxin
#15
William Berry, Colleen D'Arcy, Belinda Welsh, David Orchard, Philip S Bekhor, Susan J Robertson
No abstract text is available yet for this article.
March 26, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38528737/is-vitiligo-associated-with-an-increased-risk-of-cardiovascular-outcomes-perceptions-from-a-population-based-study
#16
JOURNAL ARTICLE
Khalaf Kridin, Niv Kafri, Arnon D Cohen
No abstract text is available yet for this article.
March 25, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38528703/a-case-of-nodular-lichen-myxedematosus
#17
JOURNAL ARTICLE
Kapil Subedi, Kashini Andrew, Pui Chi Lee
No abstract text is available yet for this article.
March 25, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38509808/atopic-dermatitis-treated-safely-with-dupilumab-during-pregnancy-and-lactation-a-case-series-of-four-patients
#18
JOURNAL ARTICLE
Narang Hong, So Yun Park, Hyung Don Kook, Dong Heon Lee, Hye Jung Jung, Mi Youn Park, Jiyoung Ahn
No abstract text is available yet for this article.
March 21, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38509804/drug-survival-of-biologics-in-psoriasis-an-australian-multicentre-retrospective-study
#19
JOURNAL ARTICLE
Samantha Ting, Patricia Lowe, Annika Smith, Pablo Fernández-Peñas
BACKGROUND: Drug survival, which refers to the time from treatment initiation to discontinuation, provides a surrogate measure of the effectiveness of a biologic in a real-world setting (J Invest Dermatol, 2015, 135, 1). The aim of this study was to determine the drug survival of biologics that are currently available in Australia. We also analysed the treatment efficacy of these biologics and reasons for discontinuation. METHODS: Retrospective data from outpatient Dermatology biologic clinics in Westmead Hospital and Royal Prince Alfred Hospital (Sydney, Australia) from April 2006 to December 2020 were collected...
March 21, 2024: Australasian Journal of Dermatology
https://read.qxmd.com/read/38504450/spitz-nevus-puzzle-red-ink-tattoo-unveiling-rare-plexiform-variants
#20
Luca Bettolini, Stefano Bighetti, Sara Rovaris, Iacopo Ghini, Piergiacomo Calzavara-Pinton, Vincenzo Maione
No abstract text is available yet for this article.
March 19, 2024: Australasian Journal of Dermatology
journal
journal
21819
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.